Printer Friendly

MEMORIAL SLOAN-KETTERING COMMENCES SAFETY TRIALS FOR CAMBRIDGE BIOTECH VACCINE ADJUVANT

 MEMORIAL SLOAN-KETTERING COMMENCES SAFETY TRIALS
 FOR CAMBRIDGE BIOTECH VACCINE ADJUVANT
 WORCESTER, Mass., May 7 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced that the Memorial Sloan- Kettering Cancer Center has completed four weeks of a Phase 1 human clinical trial to evaluate the company's proprietary QS-21 adjuvant, named Stimulon (TM), for use as a component in an immunotherapeutic for melanoma. The trial is continuing, and is expected to last approximately six months.
 The study is part of an ongoing collaboration between Cambridge Biotech Corporation, Memorial Sloan-Kettering Cancer Center and Biomira Inc., a Canadian biotechnology company. In the clinical trial, patients with melanoma are administered the Stimulon adjuvant in combination with a synthetic cancer associated antigen, named Theratope (TM), developed by Biomira, to evaluate the safety of variable dosage levels in humans.
 The potential usefulness of QS-21 for this application was established in mouse studies carried out at Memorial Sloan-Kettering. Additionally, research conducted by Cambridge Biotech Corporation and published in a number of scientific journals, has described the chemical and adjuvant properties of QS-21. Articles published in the March 1 and April 15, 1992, issues of the Journal of Immunology outlined the adjuvant's ability to promote both high levels of antibodies and strong, antigen-specific cellular immune responses. The latter are thought to be important for protection from viral infection and perhaps cancer, and are not typically generated by other adjuvants, including aluminum hydroxide, currently the only adjuvant approved for human use.
 QS-21 has been approved for veterinary use by the U.S. Department of Agriculture and is currently used in a commercially available veterinary vaccine, GenetiVac (TM) FeLV, manufactured by Cambridge. Several collaborations have been established between Cambridge and other research partners to evaluate the adjuvant as a component of other human and veterinary vaccines.
 Cambridge Biotech Corporation is a leader in the development of vaccines, adjuvants and monoclonal antibodies as the basis for vaccines, therapeutic and diagnostic products for humans and animals. The company is a major developer, manufacturer and distributor of viral diagnostic screening and confirmatory products utilizing recombinant technology.
 -0- 5/7/92
 /CONTACT: Peter P. Hartman, vice president-finance and chief financial officer of Cambridge Biotech, 508-797-5777, or Mark Cohen of Cameron Associates, 212-644-9560, for Cambridge Biotech/
 (CBCX) CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU: PDT


KD -- NY011 -- 7426 05/07/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 7, 1992
Words:389
Previous Article:HNS ANNOUNCES OPEN MARKET STOCK REPURCHASE PROGRAM
Next Article:VERTEX PHARMACEUTICALS RECEIVES NIH GRANT FOR HIV RESEARCH
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
ORAVAX AND PASTEUR MERIEUX-CONNAUGHT SUCCESSFULLY COMPLETE CLINICAL TRIAL OF WORLD'S FIRST ORAL VACCINE AGAINST PEPTIC ULCER DISEASE
PROGENICS PHARMACEUTICALS LICENSES CLINICALLY ADVANCED CANCER VACCINE FROM MEMORIAL SLOAN-KETTERING
PROGENICS PHARMACEUTICALS BEGINS PIVOTAL PHASE III CLINICAL TRIAL FOR GMK CANCER VACCINE
Progenics Pharmaceuticals Begins Phase I/II Clinical Trial for MGV
Early Clinical Results of Ligand's Novel RAR-Selective Retinoid, LGD1550 Reported at ASCO Meeting In Los Angeles
Galenica Pharmaceuticals' Immune Enhancer GPI-0100 Found To be More Effective in Stimulating an Immune Response.
CytRx forms prostate cancer alliance with Cytogen and Progenics.
AustCancer's Galenica signs materials transfer agreement with Memorial Sloan-Kettering.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters